Protalix BioTherapeutics (PLX) Debt Ratio (2011 - 2024)

Protalix BioTherapeutics (PLX) posted quarterly Debt Ratio of 0.22 for Q2 2024, down 1.87% quarter-over-quarter from 0.23 in Q1 2024.

Protalix BioTherapeutics (PLX) Debt Ratio (2011 - 2024) Analysis & Trends

Protalix BioTherapeutics' Debt Ratio history runs 11 years deep, the most recent figure standing at 0.22 for Q2 2024.

In Q2 2024, Debt Ratio changed N/A year-over-year to 0.22; the TTM figure through Jun 2024 stood at 0.22 (changed N/A YoY), while the FY2023 annual figure was 0.24, changed N/A from the prior year.
Debt Ratio for Q2 2024 stood at 0.22, down from 0.23 in the prior quarter.
The five-year high for Debt Ratio was 0.8 in Q4 2020, with the low at 0.04 in Q3 2021.
The 4-year median for Debt Ratio is 0.24 (2023), against an average of 0.35.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Protalix BioTherapeutics	189.97 Mn	149.31 Mn	12.13 Mn	-

Download Data